ABSTRACT
The human ether-a-go-go-related gene (hERG) channel plays a critical role in cardiac action potential repolarization. hERG block can lead to arrhythmia, and increased incidence of sudden death. Association of in silico and experimental approaches has been suggested as the foundation of a cost-effective preclinical evaluation of the cardiotoxic risks of drug candidates. Although several drugs have been withdrawn from the market for this reason, it has just recently been of interest to assess the potential cardiotoxic risks of botanicals. The goal of this study was to design, experimentally validate and apply a virtual screening workflow to identify novel hERG channel blockers, with a special focus on the investigation of natural products. A ligand-based pharmacophore model collection was developed and theoretically evaluated against databases of known hERG blockers from the literature and drug-like decoys. The best models were then used for virtual screening of compound libraries. Fifty chemically diverse compounds were selected from the hitlists for bioactivity testing on Xenopus laevis oocytes and HEK 293 cells using patch clamp techniques. This campaign identified 20 unknown hERG blockers, including highly potent compounds, active at the submicromolar range. The experimental confirmation that the models developed in this study can accurately predict hERG block by previously unknown compounds of natural origin is of special interest. These models are currently implemented as prediction tools in a larger ongoing EU-project (hERGscreen), aiming at target-oriented identification and isolation of hERG channel blockers from highly consumed botanicals.
Keywords: hERG; pharmacophore models; virtual screening; patch clamp; cardiac toxicity.
Jadel M. KRATZ PhD 1, 2, Daniela SCHUSTER3, Michael EDTBAUER3, Priyanka SAXENA4, Christina E. MAIR4, Julia KIRCHEBNER3, Barbara MATUSZCZAKC, Igor BABURIN4, Steffen HERING4, Judith M. ROLLINGER2
1 Departamento de Ciências Farmacêuticas, Universidade Federal de Santa Catarina, Florianópolis, SC, Brazil. [email protected] 2 Institute of Pharmacy/Pharmacognosy. 3 Institute of Pharmacy/Pharmaceutical Chemistry, Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck, Austria. 4 Department of Pharmacology and Toxicology, University of Vienna, Vienna, Austria.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Copyright Universidad de Antioquia 2014